Transenterix Inc (NYSEAMERICAN:TRXC) has received a consensus recommendation of “Hold” from the six research firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and two have issued a buy recommendation on the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $3.23.

Several research analysts have commented on the company. Ladenburg Thalmann Financial Services set a $5.00 price objective on Transenterix and gave the company a “buy” rating in a research report on Friday, October 20th. Stifel Nicolaus reissued a “buy” rating and issued a $4.00 price objective (up from $3.75) on shares of Transenterix in a research report on Monday, October 30th. Finally, BTIG Research reissued a “hold” rating on shares of Transenterix in a research report on Monday.

In related news, CFO Joseph P. Slattery sold 529,609 shares of Transenterix stock in a transaction dated Thursday, November 16th. The stock was sold at an average price of $2.80, for a total value of $1,482,905.20. Following the completion of the transaction, the chief financial officer now directly owns 440,974 shares in the company, valued at $1,234,727.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Todd Pope sold 600,000 shares of Transenterix stock in a transaction dated Wednesday, October 18th. The stock was sold at an average price of $3.68, for a total value of $2,208,000.00. Following the completion of the transaction, the insider now owns 462,644 shares of the company’s stock, valued at $1,702,529.92. The disclosure for this sale can be found here. Insiders sold 1,462,609 shares of company stock valued at $4,666,595 over the last quarter.

An institutional investor recently raised its position in Transenterix stock. Ladenburg Thalmann Financial Services Inc. increased its position in shares of Transenterix Inc (NYSEAMERICAN:TRXC) by 87.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 79,150 shares of the medical instruments supplier’s stock after purchasing an additional 37,000 shares during the period. Ladenburg Thalmann Financial Services Inc. owned 0.05% of Transenterix worth $113,000 at the end of the most recent quarter.

Shares of Transenterix (NYSEAMERICAN TRXC) traded up $0.19 on Tuesday, hitting $2.31. The company had a trading volume of 4,172,700 shares, compared to its average volume of 3,243,052. Transenterix has a twelve month low of $0.45 and a twelve month high of $5.00.

TRADEMARK VIOLATION NOTICE: This article was first posted by Daily Political and is the property of of Daily Political. If you are reading this article on another publication, it was copied illegally and reposted in violation of US and international copyright laws. The original version of this article can be read at https://www.dailypolitical.com/2017/12/19/transenterix-inc-trxc-given-average-rating-of-hold-by-analysts.html.

About Transenterix

TransEnterix, Inc is a medical device company. The Company is focused on the development and commercialization of ALF-X Surgical Robotic System (the ALF-X System), and SurgiBot System. The Company’s ALF-X System is a multi-port robotic surgery system, which allows multiple robotic arms to control instruments and a camera.

Receive News & Ratings for Transenterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transenterix and related companies with MarketBeat.com's FREE daily email newsletter.